|
May 16, 2022
|
Biora Therapeutics to Participate in Upcoming H.C. Wainwright Global Investment Conference
|
|
May 10, 2022
|
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
|
|
May 5, 2022
|
Progenity Announces Successful Transfer of Liquid Biopsy Technologies
|
|
May 3, 2022
|
Progenity to Report First Quarter Financial Results and Provide Corporate Update as Biora Therapeutics, Inc.
|
|
April 25, 2022
|
Progenity Appoints Paul Shabram to Lead Technical Operations of the Company’s Ingestible Drug/Device Platforms
|
|
April 12, 2022
|
Progenity to Become Biora Therapeutics as it Completes Transformation
|
|
April 6, 2022
|
Progenity Announces Two Poster Presentations at Controlled Release Society 2022
|
|
March 28, 2022
|
Progenity Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
|
|
March 16, 2022
|
Progenity to Report Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update
|
|
March 10, 2022
|
Progenity Progresses its Drug Delivery System Clinical Device Performance Studies
|
